Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gated CD123 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Children's Hospital Los Angeles
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Gated CD123 CAR-T cells are an engineered cellular immunotherapy designed to treat acute myeloid leukemia (AML) with improved precision. The therapy utilizes a Synthetic Notch (SynNotch) circuit that functions as an AND logic gate: the T cells constitutively express a SynNotch receptor for CD33, which, upon binding, induces the expression of a chimeric antigen receptor (CAR) specific for CD123. This sequential activation mechanism is intended to limit on-target, off-tumor toxicity by ensuring that the potent CD123-directed CAR activity is restricted to environments where both CD33 and CD123 are present, such as AML blasts, while sparing healthy tissues that express only one of the antigens. Developed by researchers at the University of Southern California and Children's Hospital Los Angeles, recent optimizations include the incorporation of high-intensity signaling modules (e.g., ZAP70-based or modified CD3ζ ITAMs) to improve cytotoxicity and metabolic fitness.
- Other names
- SynNotch-gated CD123 CAR-T cellsCD33-SynNotch-CD123-CAR-T cellsCD-33-SynNotch-CD123-CAR-T cellsCD 33-SynNotch-CD123-CAR-T cells
02
Targets
IL3RA (Interleukin 3 Receptor)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on gated CD123 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gated CD123 CAR-T cells.